105 related articles for article (PubMed ID: 26589538)
21. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid?
Fascì Spurio F; Aratari A; Margagnoni G; Doddato MT; Papi C
J Gastrointestin Liver Dis; 2012 Mar; 21(1):67-73. PubMed ID: 22457862
[TBL] [Abstract][Full Text] [Related]
22. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
23. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
[TBL] [Abstract][Full Text] [Related]
24. Advances in Pediatric Inflammatory Bowel Disease.
Maxwell EC; Grossman AB
Adolesc Med State Art Rev; 2016; 27(1):57-74. PubMed ID: 27363233
[No Abstract] [Full Text] [Related]
25. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Niederau C; Backmerhoff F; Schumacher B; Niederau C
Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
[TBL] [Abstract][Full Text] [Related]
26. Update on ustekinumab for the treatment of Crohn's disease.
Leung Y; Panaccione R
Gastroenterol Clin North Am; 2014 Sep; 43(3):619-30. PubMed ID: 25110262
[TBL] [Abstract][Full Text] [Related]
27. Early combined immunosuppression in Crohn's disease.
Badina L; Taddio A; Ventura A
Lancet; 2008 Jun; 371(9629):1995; author reply 1996-7. PubMed ID: 18555906
[No Abstract] [Full Text] [Related]
28. Meningococcal meningoencephalitis after certolizumab pegol treatment in a patient with Crohn's disease.
Majumder S; Kumar A
J Crohns Colitis; 2013 Feb; 7(1):e19. PubMed ID: 22742971
[No Abstract] [Full Text] [Related]
29. Review article: the management of severe Crohn's disease.
Parkes M; Jewell DP
Aliment Pharmacol Ther; 2001 May; 15(5):563-73. PubMed ID: 11328250
[TBL] [Abstract][Full Text] [Related]
30. Enteral nutrition as primary therapy in childhood Crohn's disease: control of intestinal inflammation and anabolic response.
Beattie RM
JPEN J Parenter Enteral Nutr; 2005; 29(4 Suppl):S151-5; discussion S155-9, S184-8. PubMed ID: 15980277
[TBL] [Abstract][Full Text] [Related]
31. Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy.
Lasson A; Strid H; Ohman L; Isaksson S; Olsson M; Rydström B; Ung KA; Stotzer PO
J Crohns Colitis; 2014 Aug; 8(8):789-95. PubMed ID: 24418661
[TBL] [Abstract][Full Text] [Related]
32. Medical treatment of Crohn's disease. Controlled trials.
Van Maele P; Willocx R
Ann Gastroenterol Hepatol (Paris); 1985; 21(4):221-6. PubMed ID: 2866752
[TBL] [Abstract][Full Text] [Related]
33. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
[TBL] [Abstract][Full Text] [Related]
34. Diet to the Rescue: Cessation of Pharmacotherapy After Initiation of Exclusive Enteral Nutrition (EEN) Followed by Strict and Liberalized Specific Carbohydrate Diet (SCD) in Crohn's Disease.
Nakayuenyongsuk W; Christofferson M; Nguyen K; Burgis J; Park KT
Dig Dis Sci; 2017 Oct; 62(10):2686-2689. PubMed ID: 28084605
[No Abstract] [Full Text] [Related]
35. Drug safety in the treatment of Crohn's disease.
Juillerat P; Felley C; Mottet C; Froehlich F; Vader JP; Burnand B; Gonvers JJ; Michetti P
Digestion; 2005; 71(1):8-12. PubMed ID: 15711042
[TBL] [Abstract][Full Text] [Related]
36. Initial combination therapy in early Crohn's disease.
Sandborn WJ
Lancet; 2008 Feb; 371(9613):635-636. PubMed ID: 18295013
[No Abstract] [Full Text] [Related]
37. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
Colombel JF; Sandborn WJ; Allez M; Dupas JL; Dewit O; D'Haens G; Bouhnik Y; Parker G; Pierre-Louis B; Hébuterne X
Clin Gastroenterol Hepatol; 2014 Mar; 12(3):423-31.e1. PubMed ID: 24184736
[TBL] [Abstract][Full Text] [Related]
38. [Crohn disease. Main symptoms: diarrhea, abdominal pain (especially right lower abdomen in ileocolitis), fatigue, weight loss].
Nigg C; Kolyvanos Naumann U; Käser L; Vetter W
Praxis (Bern 1994); 2008 Feb; 97(3):105-13; quiz 113-4. PubMed ID: 18549009
[No Abstract] [Full Text] [Related]
39. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
Herrlinger KR; Diculescu M; Fellermann K; Hartmann H; Howaldt S; Nikolov R; Petrov A; Reindl W; Otte JM; Stoynov S; Strauch U; Sturm A; Voiosu R; Ammendola A; Dietrich B; Hentsch B; Stange EF
J Crohns Colitis; 2013 Sep; 7(8):636-43. PubMed ID: 23078909
[TBL] [Abstract][Full Text] [Related]
40. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
